Post Endodontic Treatment in Diabetic Patients and Correlation with their Glycemic Status: A Study

2020 ◽  
Keyword(s):  
Endodontic Treatment ◽  
Diabetic Patients ◽  
Glycemic Status

scholarly journals Self-monitoring of Blood Glucose (SMBG): Cornerstone of Diabetes Management- Bangladesh Perspective: A Recommendation

2015 ◽  
Vol 32 (4) ◽  
pp. 218-223
Author(s):  
Zafar Ahmed Latif
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Diabetes Management ◽  
Clinical Decision ◽  
Local Context ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Self Monitoring ◽  
International Guidelines ◽  
Local Guideline

SMBG is a crucial factor in diabetes management. It offersa quick check of glycemic status, helps to identify hypoglycemia and hyperglycemia. In addition SMBG assists in clinical decision making and as such it complements HbA1c. But due to many reasons SMBG is not practiced properly and adequately. In recent years several international guidelines higllighted the importance of SMBG for diabetes management. Very few diabetic patients in Bangladesh actually perform SMBG regularly at home. The awareness of the benefits of SMBG is also low. There is no uniformity in SMBG practice among the patients as there is no local guideline to help the physicians in determining the optimum SMBG frequency for their patients. So a working guideline on SMBG is the call of the day. This article is an attempt in that direction. Exploring international guidelines and evaluating their applicability in local context a number of recommendations have been proposed.J Bangladesh Coll Phys Surg 2014; 32: 218-223

scholarly journals Comparison of Effectiveness between DPP4 inhibitors combined with Versus Other Oral Hypoglycaemic Agent(s) in Diabetic patients

2019 ◽  
Vol 30 (2) ◽  
pp. 63-70
Author(s):  
Md Shameem Haidar
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Combination Group ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Good Glycemic Control ◽  
Dpp4 Inhibitor ◽  
Number Of Patients ◽  
Inhibitor Combination

Background: Diabetes is global health burden of disease that requires life-long pharmacological and non-pharmacological management to prevent complications such as cardiovascular disease, retinopathy, nephropathy, and neuropathy. Treatment of type 2 diabetes is based on an interplay of patient characteristics, severity of hyperglycemia and available therapeutic options. Metformin, sulfonylureas (SU) and DPP IV inhibitor are the most studied of the oral medications used worldwide. They play a prominent initial role in the type 2 diabetes treatment algorithm recommended by the several guideline. The growing evidence on new technologies and therapeutic interventions is rapidly expanding our knowledge and ability to manage diabetes and its complications; at the same time, however, it is challenge for physicians to select appropriate medication in appropriate dose for optimal patients care. Objectives: To compare the safety and efficacy of the dipeptidylpeptidase-4 (DPP-4) inhibitors combination with other oral hypoglycaemic agent(s) in patients with type 2 diabetes and inadequate glycemic control. Materials & method: Study was conducted among 600 patients over a period of 24 months. All the patients were adult male and female type 2 diabetic patients who received regular oral anti-diabetic drug(s) and duration of T2DM for one year or more were enrolled for study. Total 150 cases were selected. Patients with Type 1 DM, pregnant women with DM and who was receiving injectable antidiabetic medications were excluded from this study. Detail demographic data were collected from the informant and recorded in structured case report form. Clinical examination and relevant investigations were done. Main outcome variable was Glycemic status (HbA1C, FBG, 2HABF). Effectiveness of drugs was evaluated by glycaemic status of the patients. Result: Maximum number of patients (38.5%) was between 31-40 years age group with mean age 37.8±9.5 years. Present study shows that, for good glycemic control, all three results (FBS, 2H ABF and HbA1c) were within targeted level in majority patients of DPP4 Inhibitor combination group. Although FBS was best result in metformin group. About 51.9% of SUs group achieved the glycemic control targets level. In case of metformin group it was in 59.8% of patients, and in combined therapy 67.1% patients shows good glycemic target. So DPP4 Inhibitor combination is better medication than other to maintain good glycemic status in type 2 DM patient, due to maximum number of patients reached all three components of result within target range. Conclusion: Diabetes is chronic illness. Good glycemic control with choosing appropriate anti-diabetic medication is pivotal for DM management. In this study it is observed that DPP4 Inhibitor combination group of drug is better than other anti-diabetic medication to maintain good glycemic status in type 2 DM patients. Bangladesh J Medicine July 2019; 30(2) : 63-70

scholarly journals Sex-specific Prevalence of coronary heart disease among Tehranian adult population across different glycemic status: Tehran Lipid and Glucose Study, 2008-2011

2020 ◽  
Author(s):  
Seyyed Saeed Moazzeni ◽  
Hamidreza Ghafelehbashi ◽  
Mitra Hasheminia ◽  
Donna Parizadeh ◽  
Arash Ghanbarian ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Adjusted Model

Abstract Background: Coronary heart disease (CHD) is one of the main causes of deaths. Alarmingly Iranian populations had a high rank of CHD worldwide. The current study aimed to assess the prevalence of CHD across different glycemic categories. Methods: This study was conducted on 7,718 Tehranian participants (Men=3427) aged ≥ 30 years from 2008 to 2011. They were categorized based on glycemic status. The prevalence of CHD was calculated in each group, separately. CHD was defined as hospital records adjudicated by an outcome committee. The association of different glycemic categories with CHD was calculated using multivariate logistic regression, compared with normal fasting glucose /normal glucose tolerance (NFG/NGT) group as reference. Results: The age-standardized prevalence of isolated impaired fasting glucose (iIFG), isolated impaired glucose tolerance (iIGT), both impaired fasting glucose and impaired glucose tolerance (IFG/IGT), newly diagnosed diabetes mellitus (NDM), and known diabetes mellitus (KDM) were 14.30% [95% confidence interval (CI): 13.50-15.09], 4.81% [4.32-5.29], 5.19% [4.71-5.67], 5.79% [5.29-6.28] and 7.72% [7.17-8.27], respectively. Among a total of 750 individuals diagnosed as cases of CHD (398 in men), 117 (15.6%), 453 (60.4%), and 317 (42.3%) had history of myocardial infarction (MI), cardiac procedure, and unstable angina, respectively. The age-standardized prevalence of CHD for Tehranian population was 7.71% [7.18-8.24] in total population, 8.62 [7.81-9.44] in men and 7.19 [6.46-7.93] in women. Moreover, among diabetic participants, the age-standardized prevalence of CHD were 13.10 [9.83-16.38] in men 10.67 [8.90-12.44] in women, respectively, which were significantly higher than corresponding values for NFG/NGT and prediabetic groups. Across 6 levels of glycemic status, CHD was associated with IFG/IGT [ odds ratio (OR) and 95% CI: 1.38 (1.01-1.89)], NDM [1.83 (1.40-2.41)], and KDM [2.83 (2.26-3.55)] groups, in the age and sex adjusted model. Furthermore, in the full-adjusted model, only NDM and KDM status remained to be associated with the presence of CHD by ORs of 1.40 (1.06-1.85) for NDM and 1.90 (1.50-2.41) for KDM. Conclusion: The high prevalence of CHD, especially among diabetic populations, necessitates urgent implementation of behavioral interventions among Tehranian population, according to evidence-based guidelines for the clinical management of diabetic patients.

Retrospective glycemic status of diabetic patients: Glycosylation of blood proteins in diabetes and chronic renal failure

1987 ◽  
Vol 24 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Kshama Kumari ◽  
V. Bansal ◽  
Jagmohan ◽  
C. G. Agarwal ◽  
Anil K. Rastogi ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Diabetic Patients ◽  
Blood Proteins ◽  
Glycemic Status

scholarly journals Effects ofMomordica charantiaL. on the Blood Rheological Properties in Diabetic Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Eduardo Luzía França ◽  
Elton Brito Ribeiro ◽  
Edson Fredulin Scherer ◽  
Déborah Giovanna Cantarini ◽  
Rafael Souza Pessôa ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Rheological Properties ◽  
Blood Viscosity ◽  
Room Temperature ◽  
Rheological Parameters ◽  
Diabetic Patients ◽  
Blood Disorders ◽  
Glycemic Status ◽  
Blood Samples ◽  
Whole Blood Viscosity

An evaluation of the rheological properties and the effects ofMomordica. charantiaL. (M. charantia) nanoparticles and polyethylene glycol (PEG) microspheres adsorbed withM. charantiananoparticles on the blood of hyperglycemic patients is presented. Blood samples were collected according to glycemic status: normoglycemic(N=56)and hyperglycemic(N=26). General and hematological characteristics were determined. Blood rheological parameters were determined at room temperature and under a temperature scan. We determined the effects on whole blood viscosity of treatment with an extract ofM. charantia, PEG, or PEG microspheres adsorbed with plant extract. The viscosity of the blood of hyperglycemic patients is greater than that of normoglycemic patients. Nanoparticles ofM. charantiaextracts lowered blood viscosity at equivalent rates in normo- and hyperglycemic individuals. PEG microspheres did not reduce blood viscosity in hyperglycemic individuals. However, PEG microspheres adsorbed with nanofraction extracts ofM. charantiareduced blood viscosity. These data suggest that the effects of diabetes on the viscosity of the blood should be considered. The use of a nanoparticles extract ofM. charantiaand its adsorption on PEG microspheres may represent an alternative for the control and treatment of blood disorders in diabetic patients.

scholarly journals Influence of serum albumin on HbA1c and HbA1c-defined glycemic status: a retrospective study

2020 ◽  
Author(s):  
Xiao jing Feng ◽  
Yan yi Yang ◽  
Si qi Zhuang ◽  
Yi yuan Fang ◽  
Yu feng Dai ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Serum Albumin ◽  
Threshold Effect ◽  
Albumin Level ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Increased Risk ◽  
Routine Physical Examination ◽  
Diabetic Population ◽  
High Fasting Plasma Glucose

Abstract Backgound: Glycated hemoglobin (HbA1c) is commonly used in the diagnosis and evaluation of glycemic control in diabetes, and may be influenced by several non-glycemic and glycemic factors, including albumin. This retrospective study investigated the influence of albumin on HbA1c and HbA1c-defined glycemic status. Methods: The demographic, hematological, and biochemical data were collected for 11,922 patients undergoing routine physical examination. Univariate and multivariate linear regression analyses, stratified analyses and interaction analyses, and multiple logistic regression were conducted to identify the association between albumin and HbA1c in people with different glycemic status. Results: HbA1c levels were inversely associated with serum albumin level ( P < 0.0001) in all participants. Risk factors leading to the association included age >45 years, high fasting plasma glucose (≥7.0 mmol/L), and anemia. The negative association between HbA1c and albumin was curved ( P < 0.0001) and had a threshold effect in the HbA1c-defined diabetic population; the association was significantly stronger when the albumin level fell below 41.4 g/L (β: –0.31, 95% CI: –0.45 to –0.17, P < 0.0001). A 2 g/L increase in albumin reduced the odds of HbA1c-defined dysglycemia, diabetes, and poor glycemia control by 12% to 36%, after adjustment for all possible confounders. Conclusions: HbA1c was inversely associated with albumin level in all participants, and the association was significantly stronger in people with diabetes (defined by HbA1c criteria). For diabetic patients with lower albumin level, there was an increased risk of an erroneous HbA1c-based identification and management of glycemic status.

Sign in / Sign up

Export Citation Format

Share Document